Cardiovascular Drugs Market Size, Share, Growth Analysis, By Drug Type(Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs), By End User(Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35D2041 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 64 |Figures: 75

Cardiovascular Drugs Market Insights

Global Cardiovascular Drugs Market size was valued at USD 155.6 billion in 2021 and is poised to grow from USD 162.63 billion in 2022 to USD 231.64 billion by 2030, growing at a CAGR of 4.52% in the forecast period (2023-2030).

Lack of time and physical activity among walkers has proven to be a growing factor for the cardiovascular drug market. The prevalence of hypertension in the population has increased the risk of cardiovascular disorders, which helps drive the cardiovascular drug market. The long working hours of young people in developing countries put them at increased risk of cardiovascular disorders. A large number of people are believed to have cardiovascular disease, which increases the sales and supply of related drugs. The minimum age for cardiovascular disorders has been reduced to a great extent, which makes a very favourable factor for the growth of the market. 

With the increase in the prevalence of cardiovascular diseases among the people, a rapid growth is observed in the cardiovascular drugs market. As a result of people wrong lifestyle practices and sedentary habits, the number of people suffering from cardiovascular diseases has increased tremendously. Changes in people's eating and drinking habits have also shown a significant impact on the cardiovascular system. The use of advanced technology and drugs in the market for cardiovascular drugs has seen or fallen in developing countries where people's disposable income is very low. Developed countries have a high disposable income that helps the market record a higher income return than they do. The ignorance of the public about the health facilities available to the public causes the treatment of life-threatening conditions of cardiovascular patients to be delayed. This has a direct impact on the cardiovascular drugs market. However, strict drug approval process and side effects of some cardiovascular drugs hamper the growth of global cardiovascular drugs market.

Market Snapshot - 2024-2031

Global Market Size

USD 155.6 billion

Largest Segment

Antihypertensive

Fastest Growth

Antihypertensive

Growth Rate

4.52% CAGR

Global cardiovascular drugs market, 2022-2030 ($ Bn)
Country Share for North America Region- 2022 (%)

To get more reports on the above market click here to Buy The Report

Cardiovascular Drugs Market Segmental Analysis

Global cardiovascular drugs market is segmented on the basis of drug type, end user and region. On the basis of drug type, global market is segmented into antihypertensive, anticoagulant, antihyperlipidemic, and antiplatelet. On the basis of end user, global market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. On the basis of region, global market is divided into North America, Europe, Asia Pacific, Latin America, and MEA.

Analysis by Drug Type

On the basis of drug type, global cardiovascular drugs market is segmented into antihypertensive, anticoagulant, antihyperlipidemic, and antiplatelet. Antihypertensive drugs dominate the market and are expected to grow at the fastest CAGR during the forecast period. It is due to high salt intake and age-related disorders being the most common disorder in patients. The stress level of people due to jobs and frustration is increasing and it is becoming more common in society. These drugs form a habit among consumers, which makes them buy them again and again, thus increasing the market size over time. Due to the prevalence of cholesterol, the use of antihyperlipidemic drugs has increased rapidly. An anticoagulant segment is expected to grow at a significant CAGR as the incidence of heart attacks among people increases.

Analysis by End User

On the basis of end user, global cardiovascular drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacy segment has witnessed the highest growth in global cardiovascular drugs market. This is due to the rapid demand and supply of cardiovascular drugs, which is facilitated by the simple availability of both rare and routinely used drugs. Emergency cardiovascular drugs are easily available in hospital pharmacies, which are very expensive and available only in hospitals.

Retail stores are the fastest growing segment, due to their easy access to the general public. With the growing popularity of internet shopping, online retailers are also experiencing significant growth. The demand for contactless drug delivery services has increased the demand for cardiovascular drugs through online businesses, which also provide a variety of attractive discounts and offers to attract customers. The availability of simple comparison of various accessible medicines also helps consumers to choose the right medicine.

Global cardiovascular drugs market size by drug type, 2022 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Cardiovascular Drugs Market Regional Insights

On the basis of region, global cardiovascular drugs market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. North America has witnessed the highest growth in the global cardiovascular drugs market due to the high prevalence of cardiovascular disorders in the population. Due to increasing industrialization and the popularity of fast food, the prevalence of high blood pressure and other heart diseases has increased. People's sedentary lifestyle choices, along with poor eating habits, have increased the risk of cardiovascular disease, increasing the demand for these treatments.

The Asia-Pacific market is also witnessing significant growth due to the large number of people suffering from cardiovascular diseases. The growing demand for cardiovascular drugs has significantly increased the market economy. Due to the high frequency of cardiovascular diseases in the population, the demand for cardiovascular drugs has increased significantly.

Global cardiovascular drugs market size by geography, 2022-2030
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Cardiovascular Drugs Market Dynamics

Driver

  • Increased Incidence of Cardiovascular Diseases

According to WHO, 60% to 85% of the population is sedentary. According to the CDC, approximately 31 million Americans over the age of 50 lead a sedentary lifestyle, and only one in four US adults receive recommended physical activity. This factor increases market growth.

  • Increasing FDA approvals

Product approvals are expected to increase market growth in the future. For example, in May 2022, a subsidiary of Zydus Life sciences Limited entered the U.S. to market Selexipag tablets, used to treat pulmonary arterial hypertension (PAH) in adults received provisional approval from FDA. Additionally, in February 2022, the FDA approved Norliqva (amlodipine) oral solution to treat high blood pressure, lower blood pressure, and coronary artery disease in adults and children 6 years of age and older.

Restraint

  • Lack of skilled professionals

However, strict drug approval process and side effects of some cardiovascular drugs hamper the growth of global cardiovascular drugs market.

Request Free Customization of this report to help us to meet your business objectives.

Cardiovascular Drugs Market Competitive Landscape

Global cardiovascular drugs market is highly competitive with the presence of local as well as global companies. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of global cardiovascular drugs market.

Top Player's Company Profiles

  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Abbott Laboratories
  • Johnson & Johnson
  • Eli Lilly and Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Mylan N.V.
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • AbbVie Inc.

Recent Developments

  • In February 2022, the Food and Drug Administration (FDA) expanded approval of empagliflozin (Jardiance) for use in adults with heart failure (HF), regardless of ejection fraction, to reduce the risk of cardiovascular death and HF hospitalization. The drug was approved in August 2021 to reduce the risk of cardiovascular death and HF hospitalization in adults with HF with reduced ejection fraction.
  • In May 2022, Amgen reported positive data from the Phase 2 OCEAN(a)-DOSE clinical study evaluating olpasiran (formerly AMG 890) in 281 adult patients with lipoprotein(a), or Lp(a), levels greater than 150 nmol/L. disclosed evidence of atherosclerotic cardiovascular disease (ASCVD). Olpsiran is a small interfering RNA designed to reduce the body's production of apolipoprotein (a), an important component of Lp (a) that is associated with an increased risk of cardiovascular events.

Cardiovascular Drugs Key Market Trends

  • Obesity and high cholesterol levels increase the risk of cardiovascular disease. The use of emergency medicine is commonly seen in hospitals, which has shown great potential for market growth. A large number of patients receive personal care for chronic conditions, which proves to be a steady seller for the market and continues to generate revenue returns. The use of cardiovascular drugs has also increased the prevalence of hypertension. There is a high demand for blood thinners in the market due to the increasing incidence of cardiovascular diseases. The increasing life expectancy of the elderly population has increased the demand for cardiovascular drugs. The increasing prevalence of cardiovascular disease in children has boosted the sales of these emergency drugs. Hypertensive drugs are difficult to discontinue, which helps maintain supply and demand.

Cardiovascular Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our business information services team that collects, collates, co-relates, and analyses the data collected by means of primary exploratory research backed by the robust secondary desk research.

According to our global cardiovascular drugs market analysis, based on drug type, antihypertensive drugs dominate the market and are expected to grow at the fastest CAGR during the forecast period. It is due to high salt intake and age-related disorders being the most common disorder in patients. By region, North America has witnessed the highest growth in the global cardiovascular drugs market due to the high prevalence of cardiovascular disorders in the population. However, strict drug approval process and side effects of some cardiovascular drugs hamper the growth of global market.

Report Metric Details
Market size value in 2023 USD 155.6 billion
Market size value in 2031 USD 231.64 billion
Growth Rate 4.52%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Drug Type
    • Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs
  • End User
    • Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Abbott Laboratories
  • Johnson & Johnson
  • Eli Lilly and Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Mylan N.V.
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • AbbVie Inc.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Cardiovascular Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Cardiovascular Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Cardiovascular Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cardiovascular Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cardiovascular Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Cardiovascular Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardiovascular Drugs Market size was valued at USD 155.6 billion in 2021 and is poised to grow from USD 162.63 billion in 2022 to USD 231.64 billion by 2030, growing at a CAGR of 4.52% in the forecast period (2023-2030).

cardiovascular drugs market is highly competitive with the presence of local as well as companies. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of cardiovascular drugs market. 'Pfizer Inc.', 'Novartis AG', 'AstraZeneca PLC', 'Merck & Co., Inc.', 'Sanofi S.A.', 'Bristol-Myers Squibb Company', 'Boehringer Ingelheim GmbH', 'Bayer AG', 'Abbott Laboratories', 'Johnson & Johnson', 'Eli Lilly and Company', 'Amgen Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Daiichi Sankyo Company, Limited', 'Gilead Sciences, Inc.', 'GlaxoSmithKline plc', 'Mylan N.V.', 'Takeda Pharmaceutical Company Limited', 'Astellas Pharma Inc.', 'AbbVie Inc.'

Increased Incidence of Cardiovascular Diseases

Obesity and high cholesterol levels increase the risk of cardiovascular disease. The use of emergency medicine is commonly seen in hospitals, which has shown great potential for market growth. A large number of patients receive personal care for chronic conditions, which proves to be a steady seller for the market and continues to generate revenue returns. The use of cardiovascular drugs has also increased the prevalence of hypertension. There is a high demand for blood thinners in the market due to the increasing incidence of cardiovascular diseases. The increasing life expectancy of the elderly population has increased the demand for cardiovascular drugs. The increasing prevalence of cardiovascular disease in children has boosted the sales of these emergency drugs. Hypertensive drugs are difficult to discontinue, which helps maintain supply and demand.

On the basis of region, cardiovascular drugs market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. North America has witnessed the highest growth in the cardiovascular drugs market due to the high prevalence of cardiovascular disorders in the population. Due to increasing industrialization and the popularity of fast food, the prevalence of high blood pressure and other heart diseases has increased. People's sedentary lifestyle choices, along with poor eating habits, have increased the risk of cardiovascular disease, increasing the demand for these treatments.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Report ID: SQMIG35D2041

$5,300
BUY NOW GET FREE SAMPLE